A patient who responded to thiamine therapy with reduction of lactate in the blood and cerebrospinal fluid and clinical improvement was studied. Cultured lymphoblastoid cells of this patient were found to show reduced activities of pyruvate dehydrogenase complex (PDHC) and pyruvate dehydrogenase, decreased affinity of PDHC for thiamine pyrophosphate, and defective activation of PDHC by pyruvate dehydrogenase phosphatase. PDHC deficiency in fibroblasts and biopsied muscle of this patient was also due to the decreased affinity of PDHC for thiamine pyrophosphate. A mutation in the E , a subunit containing the thiamine binding site and serine phosphorylation site regulating the activation/inactivation of PDHC was characterized by the polymerase chain reaction and DNA sequencing. A single A-G transition was identified at position 131, resulting in the substitution of Arg-44 for His-44. This mutation must be a de novo mutation because it was not found in either parent's genomic DNA. In this study, we have obtained the first evidence at the molecular level for a mutation of thiamine-responsive PDHC deficiency. (Pediutr Res 36: 340-346, 1994) 
Congenital lactic acidemia is known to be heterogeneous and to be caused by genetically determined defects in the activities of a variety of enzymes. It is most often caused by a defect in the PDHC, which catalyzes the oxidative decarboxylation of pyruvate (1). The PDHC is a multienzyme system composed of El, dihydrolipoyltransacetylase, and dihydrolipoyldehydrogenase. El is composed of two nonidentical subunits, E , a and EIP and has a tetrameric structure, a, p,. One mechanism for regulation of PDHC activity is phosphorylation/dephosphorylation of serine residues on the E l a subunit (2) . The binding site for TPP, which is an essential cofactor for Many patients with congenital lactic acidemia have been reported to show reduction of blood lactate and clinical improvement in response to thiamine administration (4, 5) . This response is thought to occur because the mutant enzyme has decreased affinity for thiamine or because thiamine stabilizes the abnormal enzyme, but it has not been studied in detail. In this article, we described for the first time the biochemical and molecular analysis of thiamine dependency in a patient with congenital lactic acidemia.
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respectively. Amino acid analysis of plasma showed an elevated alanine level at 1840 kmol/L (normal range, 220-490 p,mol/L). Repeat blood glucose concentrations and other routine blood studies were normal. The findings on EEG and ECG were unremarkable. Muscle biopsy specimens showed no significant morphologic changes. No ragged red fibers were found. Administration of thiamine was started at the age of 3 mo. He responded to thiamine therapy (100 mg/d, 25 mg/kg/d) with reduction in the concentrations of lactate in the blood (5.9 mM) and CSF (6.0 mM) as shown in Figure 1 . When the patient was 5 mo of age, the concentrations of lactate (6.9 mM) and pyruvate (0.65 mM) in the blood were elevated again. Increase of doses of thiamine (50 mglkgld) led to reduction of blood lactate and pyruvate (5.4 and 0.64 mM, respectively). Head computed tomography scan and magnetic resonance imaging scan when the patient was 8 mo of age showed no significant changes except mild atrophy. The finding on EEG was unremarkable. However, the concentrations of lactate (6.3 mM) and pyruvate (0.75 mM) in the blood increased again. When the patient was 9 mo of age, high doses of thiamine (600 mg/d, 100 mg/kg/d) led to marked reductions of lactate in the blood (3.0 mM) and CSF (3.1 mM), as shown in Figure 1 . An alanine concentration was also reduced to 330 pmol/L. After 6 mo of thiamine treatment, the patient showed an improvement of feeding and hypotonia and then gained weight and developed head control. Thiamine therapy of this patient led to the clinical improvement, consistent with the reduction of lactate.
Radioisotopes and chemicafs. [ 1 -'4~]pyruvate was obtained from NEN Research Products (Boston, MA).
["~Ideoxy ATP was purchased from Amersham International (Bucks, UK). DCA was obtained from Tokyo Kasei Kogyo (Tokyo, Japan). Other compounds were from Sigma Chemical Co. (St. Louis, MO). 
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Cell culture. Lymphoblastoid cell lines derived from the thiamine-responsive patient, his parents, and 16 diseasefree Japanese persons were established after incubation with EBV and cyclosporin A as described by Anderson and Gusella (6) . Lymphoblastoid cells were grown in RPMI 1640 medium supplemented with 15% FCS (Gibco Laboratories, Grand Island, NY). Fibroblasts were grown in Eagle's minimal essential medium (Nissui, Tokyo, Japan) with 10% FCS. Confluent cells were harvested and washed twice with PBS.
Assay of rate of decarboxylation of [I-'4~]pymvate. The rate of decarboxylation of [~-'~C ] p~r u v a t e was measured by a modification of the method of Naito et al. (7) . Briefly, lymphoblastoid cells were harvested, washed, and suspended with PBS. The cells were incubated in 0.2 mL of PBS containing 2.5 mmol/L [l-'4~]pyruvate (0.1 mCi/mmol) with or without thiamine-HC1 (4 mM) and with or without TPP (1 mM) in closed vessels at 37OC for 1 h.
Assays of PDHC and other eniymes. Three kinds of activities of PDHC in cultured lymphoblastoid cells and cultured fibroblasts were determined by a modification of the method of Naito et al. (7) . For determination of the DCA-activated activity, the harvested cells were incubated for 30 min at 37OC in PBS containing 5 mM DCA to activate PDHC. The incubation was stopped by stop solution (30 mM NaF, 30 mM DCA, 6 mM EDTA), and then ice-cold homogenizing buffer was added to the cell pellet obtained by centrifugation. The suspension was frozen rapidly, and then the PDHC activity was determined as described previously (7) . Native activity was measured without preincubation of 5 mM DCA. For assay of total activity, the homogenate was preincubated with a partially purified preparation of a broad specificity protein phosphatase from rabbit liver (8) and 3.7 mM MnCI, for 30 min at 37OC, and then the PDHC activity was measured as described above. The PDHC activities in the presence of various concentrations of TPP were measured after their additions to the assay mixture. The activity of E l in cultured lymphoblastoid cells was determined by the method of Chuang et al. (9) . The activity of DCA-activated E l was measured after preincubation with 5 mM DCA for 30 min as described above. The E l phosphatase activities in lymphoblastoid cells were determined by the method of Ito er al. (10) . The pyruvate carboxylase and phosphoenolpyruvate carboxykinase activities in cultured fibroblasts were determined by the method of Atkin et al.
(1 1).
Immunoblot analysis. PDHC was purified from ox heart, and rabbit antibodies were prepared against PDHC, E I a , and E,P proteins (12) . Immunoblot analysis was performed with these antibodies as described previously (12)-Amplification of human E,a and E l p mRNA, subcloning, and DNA sequencing. RNA isolation from lymphoblastoid cells and cDNA synthesis were performed (13) . Sets of sense and antisense oligonucleotides were designed so that the PCR products generated covered the entire nor- ma1 human cDNA sequence, and each contained an EcoRI restriction site for subcloning. The synthetic oligonucleotides for E 1 a were PDHA-A, PDHA-B, PDHA-C, and PDHA-D as described previously (13) . The synthetic oligonucleotides for E,P were PDHB-5 (5'-GGAATTCGATAGAGGACACGACCAAG-3') and P D H B -3 (5'-ATAAATTTCAACGAATTCATAT-TCAAGTCC-3') selected according to the human E I P cDNA sequence (14, 15) . Thirty-five cycles of the polymerase chain reaction were performed with a GeneArnp DNA amplification reagent kit (Perkin-Elmer Cetus, Norwalk, CT). One cycle consisted of denaturation at 94'C for 1 min, annealing at 55OC for 1 min, and extension at 72°C for 1 min. Subcloning and DNA sequencing with [35~]deoxy ATP were performed as described previously (13) .
Analysis of genomic DNA. Genomic DNA was isolated from cultured lymphoblastoid cells by the proteinase K method (13) . Specific amplification of genomic DNA encompassing the region of a point mutation detected in the mRNA of the E l a subunit of this patient was attempted with oligonucleotides PA3F (5'-TGGAGGATAATAAC-TACCTTATTCATTT-3') and PA3R (5'-ACAGTTC-CACCACAAACCTACCAC-3'). These primers were selected according to the human E l a genomic DNA sequence (16) . The DNA amplified by PCR were digested with NaeI. Protein determination. Protein concentrations during purification of ox PDHC and SDS-PAGE were determined by the method of Bradford (17) . The protein concentrations of other samples were measured by the method of Lowry et al. (18) with BSA as a standard.
Shtistical analysis. Statistical significance was determined by t test.
RESULTS

Decarboxylation of l~-'~~] p y r u v a t e
in intact lymphoblastoid cells. Intact lymphoblastoid cells from normal subjects and the thiamine-responsive patient incubated with [l-14~]pyruvate alone showed decarboxylation rates of 78.6 and 15.9 nmol/h/mg of protein, respectively, indicating an 80% decrease in the rate in the thiamineresponsive variant cells. Addition of a high concentration (4 mM) of thiamine-HCl to intact normal and thiamineresponsive cells increased the decarboxylation rates of 80.9 and 35.2 nmol/h/mg of protein, respectively, resulting in the increase of the decarboxylation rates by 2 and 121%, respectively. Addition of a high concentration (1 mM) of TPP to intact normal and thiamine-responsive cells increased the decarboxylation rates of 85.0 and 40.3 nmol/h/mg of protein, respectively, resulting in the increase of the decarboxylation rates by 8 and 153%, respectively.
Activities of PDHC and other envmes. The activities of the PDHC in cultured lymphoblastoid cells from normal subjects and the patient were assayed in three different conditions (native, DCA activated, and total) and at two different concentrations of TPP (0.4 mM and 1 x low4 mM) (Table 1 ). When assayed in the presence of 0.4 mM TPP, the DCA-activated activity of normal controls was 2-fold of native activity, whereas the DCA-activated activity of the patient was almost the same activity in native state, indicating that PDHC of this patient was not sufficiently activated by only his own endogenous E l phosphatase; the total activity, measured after in vitro activation with an excess amount of a broad specificity protein phosphatase, was within the normal range, indicating that PDHC in this patient was activated by the large amount of exogenous E, phosphatase. Furthermore, the activity of the E l phosphatase in this patient was within normal range (the patient had 226.8 and controls had 204.4 2 48.2 m u PDHC activated/min/mg protein). These results indicated that this patient had a disorder of the mechanism for activation of PDHC except E , phosphatase. In the presence of 1 x mM TPP, corresponding to the TPP concentration within normal human blood cells, all three activities of PDHC of this patient were extremely low, although no difference was observed in the PDHC activities of control cells in the presence of 0.4 mM and 1 x mM TPP. Furthermore, the activities of PDHC of his parents were within normal range in the presence of either 0.4 mM or 1 x mM TPP (data not shown). Pyruvate carboxylase and phosphoenolpyruvate carboxykinase activities of cultured fibroblasts of this patient were normal (data not shown).
A@nity of PDHC for TPP. For further explanation of why thiamine had a therapeutic effect in this patient and the addition of thiamine-HCI or TPP to intact lymphoblastoid cells from this patient increased the rate of decarboxylation of [l-14~]pyruvate, we investigated the 
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affinities of normal and mutant PDHC for TPP. As shown in Figure 2A , normal cells showed approximately 50% of the full PDHC activity in the absence of TPP, and addition of 1 x 10-"M TPP restored the full activity, the PDHC activity being constant at concentrations of more than 1 x 10-"M TPP. However, cells from the thiamine-responsive patient showed extremely low PDHC activities with TPP concentrations of 0 to 1 x 10-%M and exponential increase of activity with TPP concentration above 1 x 10-"M.
Addition of a high concentration (0.4 mM) of TPP restored up to 35% of the full PDHC activity of normal cells. These data indicated that the PDHC of this patient showed decreased affinity for TPP. The PDHC activities of both fibroblasts and biopsied muscle from this patient strictly depended on the concentration of TPP (Fig. 2%) . In normal controls, almost full activities of PDHC were observed in the presence of TPP at concentrations of more than 1 x 10-a mM. However, the PDHC activities of specimens from the patient in the presence of 1 x lo-' mM TPP were extremely low, similar to that of his lymphoblastoid cells.
TPP (mM)
TPP (mM1
Aflnity of E, for TPP. To investigate the affinity of E l for TPP, we measured the activities of DCA-activated E l in the presence of various concentrations of TPP (Fig. 3) . The activity of DCA-activated E l of controls showed approximately 30% of the full activity in the absence of TPP, and addition of 1 x lop4 mM TPP restored almost full activity. In contrast, the activity of DCA-activated E l of the patient was extremely low in the presence of 1 x lop4 mM TPP, and addition of a high TPP concentration (0.2 mM) was needed to restore 30% of the average activity of controls. Thus, the E l of this patient also showed decreased affinity for TPP.
Immunoblot analysis. lmmunoblot analyses with anti-E l a and anti-Elp antibodies showed that the levels of E , a and E , P in this patient were similar to those in normal controls (Fig. 4) . Immunoblot analysis with anti-PDHC antibody revealed no abnormalities of other components (data not shown).
Characterization of the mutation. We sequenced E l a cDNA from the patient and a normal subject and found TPP (mM) only one mutation in the second position of codon 44 (Fig. 5) . The mutation, substitution of a G nucleotide for an A, changed the amino acid histidine to arginine (CAC-CGC). This mutation was therefore designated as H44R. This nucleotide substitution created a restriction site for NaeI (GCCGGC). Subcloning and sequencing of four other clones indicated that the patient had only one amino acid change of H44R for E,a cDNA. The amplified segment corresponding to the E,P cDNA of the patient had a normal length, and no change occurred in its amino acid sequence.
Identijcation of the A-G-131 transition in genomic DNA. For identification of the A+G-131 transition in genomic DNA, an exon 3 segment of genomic DNA was amplified by PCR with primers PA3F and PA3R as illustrated in Figure 6A . The size of the product of this amplification was expected to be 233 bp. When digested with NaeI, the 233-bp fragment amplified from the patient's DNA yielded one short band (186 bp) and unclear band (47 bp) (Fig. 6B) , whereas the 233-bp fragment amplified from normal genomic DNA remained intact. The 233-bp fragments amplified from the parents of this patient were also not digested with NaeI. This exon 3 region has been analyzed in more than 30 individuals, including normal control subjects and other patients with PDHC deficiency, and no other example of this base substitution has been found.
Normal Mutant
DISCUSSION
Many reports of clinical response to thiamine in patients with congenital lactic acidemia have been published, but most cases have not been characterized biochemically to be certain that true thiamine dependence exists. In this study, the clinical thiamine response in our patient was well confirmed by in vitro studies showing a thiamine-responsive functional PDHC defect in several different cell types. Furthermore, we have obtained the first evidence at the molecular level for a mutation of thiamine-responsive PDHC deficiency. Cultured lymphoblastoid cells derived from our patient showed reduced activities of PDHC and El, decreased affinity of PDHC for TPP, and defective activation of PDHC. The decreased affinity of PDHC for TPP shown in cultured lymphoblastoid cells was confirmed in cultured fibroblasts and biopsied muscle. These results suggested that various organs of this patient might show thiamineresponsive PDHC deficiency resulting in congenital lactic acidemia. In intact cultured lymphoblastoid cells of our patient, addition of a high concentration of thiamine-HCI or TPP markedly increased the rate of [l-14~]pyruvate decarboxylation. These results have been related to the observed decreases in blood lactate and CSF lactate after institution of thiamine therapy in this patient, indicating that this patient is indeed thiamine responsive and that therapeutic treatment with a high dose of thiamine is effective for treatment of congenital lactic acidosis caused by thiamine-responsive PDHC deficiency. No effective therapy for congenital lactic acidemia has yet been established. Therefore, diagnosis of thiamineresponsive PDHC deficiency is very important, because it may be possible to control lactic acidemia in this type of PDHC deficiency by a large dose of thiamine. PDHC deficiency has been diagnosed by measuring the activity of PDHC at high concentrations of TPP (0.1-0.7 mM) by several groups (7, 9, 19, 20) . However, to diagnose PDHC deficiency caused by the decreased affinity of PDHC for TPP, it is necessary to measure activities of PDHC not only at high concentration but also at low concentration of TPP, especially at lower than 1 x lo-' mM concentration.
Most of the PDHC deficiencies are due to a mutation of E l a gene located in the p22.1 to p22.2 region of the X chromosome (13, (21) (22) (23) (24) (25) . Most of them have been located near the C-terminus of EIa, and little is known about how the mutations affect the structure or function of the PDHC. In our patient, the mutation is located near the N-terminus of E1a, and the reading frame remains intact. This mutation was identified at nucleotide position 131 of the E I a subunit, resulting in the substitution of Arg-44 for His-44. The following lines of evidence indicate that the H44R mutation found in this case accounts for the thiamine-responsive PDHC deficiency. First, results on enzymatic activity suggested that the mutation might be located on E l (E,a or EIP). Second, point mutation was most likely to be located in the coding region of E I a or E,P because the defect was associated with normal levels and sizes of E I a and EIP proteins. Third, no other mutation was found in the coding region of E,a or EIP. This mutational change was unlikely to be caused by protein polymorphism because no such polymorphism has been found in any multiple human E I a cDNA sequenced by us or others (15, 21, (26) (27) (28) and because the mutated histidine (amino acid 44) found in this patient is conserved in mammalian E l & of the porcine muscle, pig heart, and rat liver (29) (30) (31) . Fourth, the H44R mutation was not found in the E,a subunit of this patient's parents, who had normal PDHC activity, indicating that this mutational change is not a polymorphism but a de novo mutation. These points of evidence support the idea that the H44R mutation results in a decreased affinity of PDHC for TPP and a defective activation of PDHC. Further investigations are required to explain the structure-function implications of the H44R mutant protein.
To our knowledge, until now only three patients with PDHC deficiency clinically improved after supplementation with thiamine (21, 32, 33) . The immunochemical analysis in these three cases has demonstrated different patterns; in patient 1 (21), the band of E I a subunit was missing, and, instead, an additional band was detected below protein X. However, in patient 2 [patient cited by Old and DeVivo (32) ], the amount of E I a subunit was comparable with that in control, but its electrophoretic mobility was altered. In patient 3 (33), E I a and EIP were undetectable, and E2 and E3 were decreased. These immunochemical analyses indicated that defects of PDHC in these three patients are due to the different abnormality. Our patient, although responsive to thiamine clinically, may be genetically different from three patients because immunoblot patterns in our patient were essentially the same as in controls, which differs from the previously described cases, and therefore our patient is an original case of thiamine-responsive PDHC deficiency.
